The methicillin-resistant staphylococcus aureus (MRSA) drugs market studied was anticipated to grow with a CAGR of nearly 3.6%, during the forecast period. The major factors attributing to the growth of the MRSA drugs market are a rise in the global prevalence of MRSA infections, a rise in private and public funding for R&D of novel anti-MRSA drug molecules and their improved screening. For instance, According to the CDC, 2% of the general population carries MRSA. Additionally, the increased practice of prescribing unnecessary and inappropriate antibiotics resulting in the rise of MRSA infections is likely to drive the growth of the global MRSA drug market.
Scope of the Report
Staphylococcus aureus is an important pathogen known to be associated with various forms of infections in humans, pets, and poultry. But over the decades, MRSA has become resistant to beta-lactam antibiotic called methicillin. In chickens, this pathogen is associated with several disease manifestations such as comb necrosis, lameness, and septicemia. Also, MRSA usually spreads in the community by contact with infected people or things that are carrying the bacteria, which fuels high demand to form effective treatment, and driving the market.
Key Market Trends
Lipopeptide Segment is Expected to Hold the Largest Market Share in the Methicillin-Resistant Staphylococcus Aureus Drugs Market
- Lipopeptide segment accounts for the major market share owing to the novel antibiotic therapy introduced for MRSA. The therapy includes daptomycin, a lipopeptide class of drug and linezolid, an oxazolidinone class of antibiotics. The rapid implementation of therapy globally fuelled the market.
- The glycopeptides and lipoglycopeptides segment is expected to show significant growth, owing to the increasing focus of manufacturers on the development of advanced drugs in this class.
- Parenteral route of administration accounted for the highest market share due to increased investment by pharmaceutical manufacturers to boost the production of intravenous anti-MRSA antibiotics.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall MRSA drug market, throughout the forecast period. This dominance is mainly due to the investments by U.S. based companies in the R&D of screening tools for MRSA infection. Also, the rise in government support to treat MRSA lung infection in individuals with cystic fibrosis has fueled the market. For instance, in 2018, Cystic Fibrosis Foundation, at North American Cystic Fibrosis Conference announced that it will spend at least USD 100 million over the next five years to support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.
Europe is the second most prominent region in the global MRSA drugs market, which is due to research grants by the public & private players in the European countries to propel the R&D of anti-MRSA antibiotics.
The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India is estimated to fuel the growth of the MRSA drugs market in the Asia Pacific.
The MRSA drug market is moderately competitive and consists of several prominent industry players. Some prominent players are acquiring blockbuster products in the market and expanding their market position. For instance, in 2018, Cumberland Pharmaceuticals Inc. acquired VIBATIV injection, an effective lipoglycopeptide class of drugs to treat MRSA, from Theravance Biopharma US, Inc. Whereas, other companies are making partnerships to consolidate their market leadership across the globe and while others are having new products in their pipeline. Some of the companies which are currently dominating the market are Melinta Therapeutics Inc., Allergan, Inc., Pfizer, Inc. Cumberland Pharmaceuticals Inc. and Merck & Co. Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support